Coeptis Pharmaceuticals

A catalyst for developing
therapies that improve
outcomes.

Our Pipeline

Coeptis’ pipeline is evolving from the partnerships being created with multiple pharmaceutical companies currently. As these relationships unfold, the product pipeline will be updated accordingly.

Partnerships

Our current business model is designed around commercializing and furthering the development of our products, as well as entering into license agreements and strategic partnerships in exciting, new therapeutic areas such as auto-immune diseases and oncology. Coeptis continually seeks partnership opportunities with companies that have novel therapies in development or companies with technologies that improve the way that drugs are delivered to patients.

Investor Relations

Coeptis Pharmaceuticals is a wholly-owned subsidiary of Vinings Holdings Inc. Vinings Holdings Inc.’s common stock is currently quoted on the OTC PINK (an interdealer electronic quotation system operated by OTC Markets Group, Inc.) under the symbol “NDYN.” Our Investor Relations page is for the benefit of investors in Vinings Holdings Inc.

For further updates, visit our Investor Relations page by clicking here.

ABOUT COEPTIS

Leadership

Dave Mehalick – President & CEO
Christine Sheehy – Chief Financial Officer
Dan Yerace – Vice President, Operations
Gary Conte – Senior Vice President, Sales and Marketing

Dave Mehalick – President & CEO

Christine Sheehy – Chief Financial Officer

Dan Yerace – Vice President, Operations

Gary Conte – Senior Vice President, Sales and Marketing

 

History

Coeptis Pharmaceuticals, LLC was formed in July 2017
and was later incorporated as Coeptis Pharmaceuticals, Inc, in
November 2018. Coeptis focuses on the development and/or
acquisition of pharmaceutical products which offer improvements
to current therapies; thereby, improving patient outcomes.

Coeptis Pharmaceuticals, LLC was formed in July 2017 and was later incorporated as Coeptis Pharmaceuticals, Inc, in November 2018. Coeptis focuses on the development and/or acquisition of pharmaceutical products which offer improvements to current therapies; thereby, improving patient outcomes.

Coeptis has licensing agreements with royalites in place with its partners and does not wholly own its products.

PRODUCTS
CONTACT
* Consensi® was developed by Purple Biotech Ltd. and is distributed by Burke Therapeutics. ** Conjupri™ was developed by CSPC OUYI Pharmaceutical Co., Ltd. and is distributed by Burke Therapeutics.
PRODUCTS

Coeptis has royalty agreements in place with its partners and does not wholly own its products.